objective: We aimed to explore the effects of metformin on oral squamous cell carcinoma (OSCC) cell proliferation and the associated molecular mechanisms.
methods: We established an OSCC model in SCC15 cells overexpressing nerve growth factor receptor (NGFR) or the N-terminal region (aa 1-250; NGFR-N), and assessed cell proliferation by CCK-8 assay, colony formation assay, and cell cycle analysis. Levels of NGFR and related genes and proteins were detected by qPCR and western blotting, and NGFR and NGFR-N affinity for p53 was assessed by immunoprecipitation assay. Additionally, the effects of NGFR and NGFR-N on p53 binding with its downstream gene promoters were analyzed by chromatin immunoprecipitation.
result... More
objective: We aimed to explore the effects of metformin on oral squamous cell carcinoma (OSCC) cell proliferation and the associated molecular mechanisms.
methods: We established an OSCC model in SCC15 cells overexpressing nerve growth factor receptor (NGFR) or the N-terminal region (aa 1-250; NGFR-N), and assessed cell proliferation by CCK-8 assay, colony formation assay, and cell cycle analysis. Levels of NGFR and related genes and proteins were detected by qPCR and western blotting, and NGFR and NGFR-N affinity for p53 was assessed by immunoprecipitation assay. Additionally, the effects of NGFR and NGFR-N on p53 binding with its downstream gene promoters were analyzed by chromatin immunoprecipitation.
results: Metformin inhibited OSCC cell proliferation and blocked NGFR proteolysis, thereby reducing the generation of its intracellular domain and NGFR-N. Moreover, compared with NGFR, NGFR-N showed higher affinity for p53 and more strongly inactivated p53 to promote cell proliferation. Furthermore, upregulation of NGFR-N downregulated levels of p53-specific downstream transcripts and proteins, whereas these levels were significantly upregulated in metformin-treated cells overexpressing NGFR.
conclusions: These results showed that metformin inhibited cell proliferation by suppressing NGFR proteolysis, thereby promoting its antitumor effect in OSCC and offering novel insight into a role for metformin in OSCC treatment.
